WASHINGTON — Eli Lilly said Thursday that it would increase the prices of medicines in Europe and other developed markets “in order to make them lower” in the U.S., in an apparent response to the Trump administration’s calls to do so. It singled out the list price of its popular weight-loss drug in the U.K. as…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we talk about how moves by the Trump administration are impacting investment in mRNA, see the law firm DLA Piper create a coalition to lobby on Medicare price negotiations, and more. Under Trump, is…
In an unexpected move, the Trump administration signaled recently that it may rely on a controversial federal law to sidestep Harvard University patents that emerged with the help of U.S. government funding. At issue is a provision of the Bayh-Dole Act, which was enacted 45 years ago to enable universities, nonprofits, and small businesses to…
WASHINGTON — A handful of drug companies have formed a group to present lawmakers with research on what the industry sees as the negative impacts of Medicare drug price negotiations, according to lobbying records. The group is called the IRA Watchdog after the Inflation Reduction Act, which directed Medicare to negotiate the prices for some…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One new study suggests it may — my colleague wrote about these…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I recently learned that there’s a market for branded drug pens. If you have some, hold on to them — they could one day become vintage collectables. Let’s get into the news…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we discuss lots of government maneuvering that impacts biopharma — starting, of course, with the FDA reinstating Vinay Prasad as the director of CBER. We also talk about President Trump’s executive order about federal research grants,…
Patient advocacy groups are urging the South African government to reopen an antitrust investigation into Vertex Pharmaceuticals over allegations the company misled authorities into closing a high-profile case last year over access to a cystic fibrosis treatment. Last December, the Competition Commission ruled that the company had sufficiently provided access to its medication after a…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, we read about the implications of mRNA funding cuts on national security, see layoffs at gene-editing player Tune Therapeutics, and more. Why mRNA funding cuts are a national security issue Health…
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. I was reminded recently of why I dig mass transit upon overhearing the train conductor and two middle-aged men engaged in a serious talk…